Key result
Type 2 diabetes patients failed to upregulate their endogenous GLP-1 system during STEMI, whereas non-diabetic patients showed sharply elevated total and active GLP-1 at 24 hours.
Why the study?
Does the endogenous GLP-1 system response differ between type 2 diabetes and non-diabetic patients during STEMI?
Observational (n=103)
Does the endogenous GLP-1 system response differ between type 2 diabetes and non-diabetic patients during STEMI?
Answers are grounded in this paper and cite their sources.
Patients with type 2 diabetes fail to upregulate their endogenous GLP-1 system during STEMI, which may contribute to their worse cardiovascular outcomes.
We previously demonstrated increased glucagon-like peptide-1 (GLP-1) secretion during acute ST elevation myocardial infarction (STEMI) in non-diabetic (ND) patients. Whether the endogenous GLP-1 system response is different in patients with type 2 diabetes (T2D) during STEMI is unknown. Patients with STEMI (20 ND, 13 T2D) and 3 control groups (non-STEMI [14 ND, 13 T2D], stable angina pectoris [SAP] [8 ND, 10 T2D] patients and healthy subjects) (n = 25) were studied. Plasma levels of total and active GLP-1 and soluble dipeptidyl peptidase-4 (sDPP4) were estimated by enzyme-linked immunosorbent assay on admission and at 24 and 48 hours after percutaneous coronary intervention in all patients. Sharply elevated levels of total and active GLP-1 were found in ND STEMI patients at 24 h (P < 0.05 and P < 0.005, respectively), but not in T2D STEMI patients. All patients demonstrated decreased sDPP4 levels compared with healthy controls (P < 0.0005) accompanied by increased active/total GLP-1 ratio regardless of their ischemic state. These data demonstrate that T2D patients fail to further upregulate their endogenous GLP-1 system during STEMI. This may underlie their worse cardiovascular outcome.
No takes yet. Share an insight, caveat, or question.
Elbaz‐Greener et al. (2018) conducted an observational in ST-elevation myocardial infarction and Type 2 Diabetes (n=103). Type 2 diabetes vs. Non-diabetic status was evaluated on Plasma levels of total and active GLP-1 at 24 hours (p=<0.05). Type 2 diabetes patients failed to upregulate their endogenous GLP-1 system during STEMI, whereas non-diabetic patients showed sharply elevated total and active GLP-1 at 24 hours.
Synapse has enriched 10 related papers. Consider them for comparative context: